Infant Bacterial Therapeutics
44.30 SEK
+1.96 %
Less than 1K followers
IBT B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+1.96 %
-27.85 %
-45.64 %
-23.75 %
-17.35 %
-29.91 %
-19.16 %
-65.39 %
-24.23 %
Infant Bacterial Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory bowel diseases. The company develops, among other things, medicines to treat and prevent common conditions and diseases in children that occur at early birth. The business is global with a primary presence in Europe and North America. Infant Bacterial Therapeutics was founded in 2011 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
596.78M SEK
Turnover
150.82K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
6/2
2026
Annual report '25
7/5
2026
Interim report Q1'26
25/8
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
IBT changes the IBP-9414 pathway for approval following discussions with the FDA
Infant Bacterial Therapeutics AB säkerställer partnerskap med Recipharm Advanced Bio för produktion av läkemedelssubstans
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools